Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research
Press Release
Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies
New microdose formats extend Optimi’s psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country’s Authorized Prescriber Scheme
VANCOUVER, BC, June 16, 2026 – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi”), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.
Microdosing refers to taking low, sub-perceptual doses of a psychedelic on a repeated schedule. Common regimens include the Fadiman protocol (one day on, two days off) and the Stamets protocol (four days on, three days off), which build in rest days to limit tolerance.
CEO and Co-Founder Dane Stevens said: “Most microdosing relies on dried mushrooms, whose psilocybin content varies widely from batch to batch. Optimi’s capsules instead deliver naturally derived psilocybin at a validated, consistent dose, pairing the natural source many researchers prefer with the accurate dosage that controlled research requires. The 1mg and 2mg dosage formats extend Optimi’s psilocybin range, which already includes the 5 mg capsule formulation currently prescribed for treatment-resistant depression in Australia.”
Optimi produces these products start to finish in-house, cultivating and harvesting the mushrooms, generating a full-spectrum mushroom extract as the active pharmaceutical ingredient (API), and formulating, encapsulating, and packaging the finished product for export to clinical research organizations. Every stage is completed on-site Optimi’s wholly owned GMP facility in Princeton, British Columbia, Canada, under its Health Canada Drug Establishment License (DEL).
Optimi supplies finished psilocybin and MDMA drug products to regulated markets internationally, supporting both patient access and clinical research. Inquiries about product supply for special access programs and clinical trials may be directed to sales@optimihealth.ca.
About Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
For more information, please visit www.optimihealth.ca or optimi.net.
For more information, please contact: Dane Stevens, CEO, Optimi Health Corp., (778) 761-4551, investors@optimihealth.ca, www.optimihealth.ca; Investor Relations Contact: Lucas A. Zimmerman, Managing Director, MZ Group – MZ North America, (262) 357-2918, OPTHF@mzgroup.us, www.mzgroup.us; InvestorWire Service Contact: IBN, Austin, Texas, www.InvestorBrandNetwork.com, 512.354.7000 Office, Editor@InvestorBrandNetwork.com
ILR4
